Market revenue in 2023 | USD 5.2 million |
Market revenue in 2030 | USD 10.3 million |
Growth rate | 10.3% (CAGR from 2023 to 2030) |
Largest segment | Biorepository services |
Fastest growing segment | Biorepository Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biorepository Services, Archiving Solution Services |
Key market players worldwide | Azenta Inc, Thermo Fisher Scientific Inc, Precision for Medicine, Medpace Holdings Inc, Labcorp Drug Development, ATCC, Q2 Solutions, LabConnect, Charles River Laboratories International Inc |
Biorepository services was the largest segment with a revenue share of 65.38% in 2023. Horizon Databook has segmented the UAE clinical trial biorepository & archiving solutions market based on biorepository services, archiving solution services covering the revenue growth of each sub-segment from 2018 to 2030.
Growing prevalence of diabetes and cardiovascular diseases in the UAE is expected to increase the demand for treatment options, boosting the need for clinical trial studies for the same. Along with the presence of a vast patient pool, quicker and well-defined regulatory approval procedure in the country is expected to contribute to market growth.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account